Severe Achromobacter xylosoxidans infection and loss of sputum bacterial diversity in an adult patient with cystic fibrosis

Paediatric Respiratory Reviews

Volumn 20, Issue , 2016, Pages 27-29

  Talbot, Nick P ^a,b   Flight, William G ^a  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Achromobacter xylosoxidans; Cross infection; Cystic fibrosis; Sputum microbiome

Indexed keywords

AZITHROMYCIN; COLISTIN; ETHAMBUTOL; ITRACONAZOLE; MINOCYCLINE; PREDNISOLONE; RIFAMPICIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACHROMOBACTER XYLOSOXIDANS; ASPERGILLUS FUMIGATUS; ATYPICAL MYCOBACTERIOSIS; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL INFECTION; CROSS INFECTION; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DISEASE TRANSMISSION; DYSPNEA; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HUMAN; LUNG FUNCTION; LUNG TRANSPLANTATION; MICROBIAL DIVERSITY; MYCOBACTERIUM INTRACELLULARE; NONHUMAN; OXYGEN THERAPY; PHYSIOTHERAPY; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SPUTUM ANALYSIS; TREATMENT DURATION; ACHROMOBACTER DENITRIFICANS; ADULT; CASE REPORT; GRAM-NEGATIVE BACTERIAL INFECTIONS; MALE; MICROBIOLOGY; PATHOGENICITY; SPUTUM;

ACHROMOBACTER DENITRIFICANS; ADULT; ANTI-BACTERIAL AGENTS; CROSS INFECTION; CYSTIC FIBROSIS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LUNG TRANSPLANTATION; MALE; SPUTUM;

EID: 84979649675     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2016.06.011     Document Type: Review

References (20)

1. [1] Coward, A., Kenna, D.T., Perry, C., Martin, K., Doumith, M., Turton, J.F., Use of nrdA gene sequence clustering to estimate the prevalence of different Achromobacter species among Cystic Fibrosis patients in the UK. J Cyst Fibros 15 (2016), 479–485.
2. [2] Spilker, T., Vandamme, P., LiPuma, J.J., Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros 12 (2013), 298–301.
3. [3] Hansen, C.R., Pressler, T., Høiby, N., Gormsen, M., Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J Cyst Fibros 5:4 (2006), 245–251.
4. [4] Otero, L.L., Girón Moreno, R., Buendía Moreno, B., Valenzuela, C., Guiu Martínez, A., Alarcón Cavero, T., Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid. Enferm Infecc Microbiol Clin 34:3 (2016), 184–187.
5. [5] De Baets, F., Schelstraete, P., Van Daele, S., Haerynck, F., Vaneechoutte, M., Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 6:1 (2007), 75–78.
6. [6] Tan, K., Conway, S.P., Brownlee, K.G., Etherington, C., Peckham, D.G., Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol 34:2 (2002), 101–104.
7. [7] Qvist, T., Taylor-Robinson, D., Waldmann, E., Olesen, H.V., Hansen, C.R., Mathiesen, I.H., et al. Comparing the effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros 15:3 (2016), 380–385.
8. [8] Romano, L., Bellodi, S., Lagani, F., Manno, G., Alcaligenese as a pathogen in airways chronic infection in cystic fibrosis. Pediatr Pulmonol 35:5 (2003), 412–413.
9. [9] Wang, M., Ridderberg, W., Hansen, C.R., Høiby, N., Jensen-Fangel, S., Olesen, H.V., et al. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J Cyst Fibros 12:6 (2013), 638–643.
10. [10] Blainey, P.C., Milla, C.E., Cornfield, D.N., Quake, S.R., Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis. Sci Transl Med, 4(153), 2012, 153ra130.
11. [11] Cox, M.J., Allgaier, M., Taylor, B., Baek, M.S., Huang, Y.J., Daly, R.A., et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One., 5(6), 2010, e11044.
12. [12] Zhao, J., Schloss, P.D., Kalikin, L.M., Carmody, L.A., Foster, B.K., Petrosino, J.F., et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A. 109:15 (2012), 5809–5814.
13. [13] Flight, W.G., Smith, A., Paisey, C., Marchesi, J.R., Bull, M.J., Norville, P.J., et al. Rapid detection of emerging pathogens and loss of microbial diversity associated with severe lung disease in cystic fibrosis. J Clin Microbiol 53:7 (2015), 2022–2029.
14. [14] Harris, J.K., De Groote, M.A., Sagel, S.D., Zemanick, E.T., Kapsner, R., Penvari, C., et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A. 104:51 (2007), 20529–20533.
15. [15] Goddard, A.F., Staudinger, B.J., Dowd, S.E., Joshi-Datar, A., Wolcott, R.D., Aitken, M.L., et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci U S A 109:34 (2012), 13769–13774.
16. [16] Parnham, M.J., Haber, V.E., Giamarellos-Bourboulis, E.J., Perletti, G., Verleden, G.M., Vos, R., Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther 143:2 (2014), 225–245.
17. [17] Kanellopoulou, M., Pournaras, S., Iglezos, H., Skarmoutsou, N., Papafrangas, E., Maniatis, A.N., Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis 23:4 (2004), 336–339.
18. [18] Van Daele, S., Verhelst, R., Claeys, G., Verschraegen, G., Franckx, H., Van Simaey, L., et al. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center. J Clin Microbiol 43:6 (2005), 2998–3002.
19. [19] Peltroche-Llacshuanga, H., Kentrup, H., Haase, G., Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis. Eur J Clin Microbiol Infect Dis 17:2 (1998), 132–134.
20. [20] Ridderberg, W., Bendstrup, K.E., Olesen, H.V., Jensen-Fangel, S., Nørskov-Lauritsen, N., Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros 10:6 (2011), 466–469.